Compelling novel cancer targets with promise of low on-target, off-tumor toxicity
BARCELONA, Spain I July 6, 2022 I La Merie Publishing released today a report bundle entitled “Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis”.
This causes a man to have less control over erections and may result in the inability to achieve an erection at all. When your condition is sertralin online kaufen Tchibanga severe, you should be treated in hospital. How does neurontin work?neurontin (neurontin) (trade name lyrica) is used to treat migraines and tension headache.
In such a situation the hospital gets the profit and the doctor gets nothing. Generic levitra is only available viagra cialis levitra quale il migliore in this pharmacy. It is used to help with symptoms of osteoarthritis, rheumatoid arthritis, fibromyalgia, and other forms of arthritis.
This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity. As such, drug modalities with enhanced effector function, e.g. antibody-drug conjugates, T cell- and NK-cell redirecting antibodies and chimeric antigen receptor (CAR) T-cells, can be employed for generation and development of novel drug candidates.
Furthermore, preclinical and preliminary clinical study results indicate a high probability of efficacy and low safety risk. And, the competitive pipeline for each target has not yet advanced too far and allows new entrants into the race good chances for success.
These four targets are covered by the reports:
- Claudin-6;
- Cadherin-17;
- ROR1; and
- GPRC5D
The reports describe and analyze the target expression profile, provide preclinical and clinical efficacy and safety data; describe potential indications and the respective paptient population, assess the competitive landscape; provide specific profiles of drug candidates in R&D and specific profiles of industry stakeholders.
The reports were prepared in May and June of 2022. The bundle of four reports is available with a 30% discount on list prices.
The report bundle Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/claudin-6-cadherin-17-ror1-and-gprc5d-targeted-therapies-target-expression-profile-safety-efficacy-of-drug-modalities-pipeline-review-and-competitive-landscape-analysis/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and at selected Resellers.
To leverage its expertise and knowledge accumulated in the in-house database, La Merie Publishing offers custom report preparation services for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing